Antengene, K2 Therapeutics deal signals fresh momentum for solid tumor TCEs
Find out how Antengene’s ATG-106 licensing deal could shape the next phase of solid tumor T cell engager development.
Pharma & Biotech
Pharma & Biotech
What Arcus Biosciences’ STAR-221 failure reveals about TIGIT fatigue in immunotherapy
Arcus Biosciences, Inc. has terminated its global Phase 3 STAR-221 study evaluating domvanalimab, an investigational anti-TIGIT antibody, in combination with zimberelimab and chemotherapy for advanced upper gastrointestinal cancers. The discontinuation, announced in partnership with Gilead Sciences, Inc., followed a pre-specified interim overall survival analysis that found no benefit compared to the nivolumab-based control arm. Arcus